About Teitur Trophics
Teitur Trophics is a company based in Aarhus (Denmark) founded in 2020 by Mathias Kaas Ollendorff, Simon Molgaard, Anders Dalby, and Simon Pedersen. Teitur Trophics has raised $29.99 million across 2 funding rounds from investors including BioInnovation Institute, Sunstone and Sound Bioventures. The company has 10 employees as of November 30, 2024. Teitur Trophics offers products and services including Cyclic Peptides Therapeutics and Biomarker Development. Teitur Trophics operates in a competitive market with competitors including The Fertility Partners, George Institute, HD, Arialys and Novus Diagnostics, among others.
- Headquarter Aarhus, Denmark
- Employees 10 as on 30 Nov, 2024
- Founders Mathias Kaas Ollendorff, Simon Molgaard, Anders Dalby, Simon Pedersen
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Teitur Trophics Aps
-
Annual Revenue
Not available
-
Net Profit
-$523.28 K (USD)47as on Dec 31, 2022
-
EBITDA
Not available
-
Total Equity Funding
$29.99 M (USD)
in 2 rounds
-
Latest Funding Round
$29.99 M (USD), Series A
Mar 14, 2023
-
Investors
BioInnovation Institute
& 5 more
-
Employee Count
10
as on Nov 30, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Teitur Trophics
Teitur Trophics offers a comprehensive portfolio of products and services, including Cyclic Peptides Therapeutics and Biomarker Development.
Therapeutics targeting neurodegenerative diseases for improved patient outcomes.
Compounds for identifying and treating Huntington’s Disease effectively.
People of Teitur Trophics
Unlock access to complete
Unlock access to complete
Funding Insights of Teitur Trophics
Teitur Trophics has successfully raised a total of $29.99M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $29.99 million completed in March 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Teitur Trophics
Teitur Trophics has secured backing from 6 investors, including venture fund investors. Prominent investors backing the company include BioInnovation Institute, Sunstone and Sound Bioventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made by Sunstone in early-stage European companies.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Venture capital investment in early-stage technology, life science, and Health startups
|
Locked | Locked | Locked |
Investor details for Teitur Trophics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Teitur Trophics
Investment portfolio details for Teitur Trophics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Teitur Trophics
Detailed financials for Teitur Trophics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Teitur Trophics Comparisons
Peer comparison for Teitur Trophics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Teitur Trophics
Teitur Trophics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as The Fertility Partners, George Institute, HD, Arialys and Novus Diagnostics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Business consulting services for fertility practices are provided.
|
|
| Locked | Locked | Locked |
Medical research is conducted by the institute in health fields.
|
|
| Locked | Locked | Locked |
Medical information services are provided in the healthcare sector.
|
|
| Locked | Locked | Locked |
Precision medicines for autoimmune neuropsychiatric diseases are developed.
|
|
| Locked | Locked | Locked |
Provider of diagnostic information services for clinicians
|
|
| Locked | Locked | Locked |
Provider of medical information solutions
|
Detailed competitors of Teitur Trophics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Teitur Trophics
Complete news archive for Teitur Trophics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Teitur Trophics
Teitur Trophics was founded in 2020.
Teitur Trophics is headquartered in Aarhus, Denmark.
Simon Molgaard is the current CEO of Teitur Trophics. They have also founded this company.
Teitur Trophics is a funded company, having raised a total of $29.99M across 2 funding rounds to date.
As of Nov 30, 2024, the latest employee count at Teitur Trophics is 10.
Teitur Trophics was established in 2020 in Aarhus, Denmark, by co-founders Mathias Kaas Ollendorff, Simon Molgaard, Anders Dalby, and Simon Pedersen. Development services for therapeutics targeting neurodegenerative diseases are offered within the biotechnology sector. Operations emphasize research and innovation in treatment pipelines. The company maintains its headquarters in Denmark, supporting global efforts in health advancements through targeted therapeutic solutions.
Teitur Trophics's top competitors include George Institute, The Fertility Partners and HD.
Teitur Trophics offers Cyclic Peptides Therapeutics and Biomarker Development.
Teitur Trophics has 6 investors. Key investors include BioInnovation Institute, Sunstone, Sound Bioventures, Innovestor, and Industrifonden.